CLINICAL TRIALS PROFILE FOR PENICILLAMINE
✉ Email this page to a colleague
All Clinical Trials for penicillamine
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00003751 ↗ | Penicillamine, Low Copper Diet, and Radiation Therapy in Treating Patients With Glioblastoma | Completed | National Cancer Institute (NCI) | Phase 2 | 1999-03-01 | RATIONALE: Penicillamine may stop the growth of glioblastomas by stopping blood flow to the tumor. A diet low in copper may interfere with the growth of brain tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining these therapies may be effective in treating glioblastoma. PURPOSE: Phase II trial to study the effectiveness of penicillamine, a low copper diet, and radiation therapy in treating patients who have newly diagnosed glioblastoma. |
| NCT00003751 ↗ | Penicillamine, Low Copper Diet, and Radiation Therapy in Treating Patients With Glioblastoma | Completed | Sidney Kimmel Comprehensive Cancer Center | Phase 2 | 1999-03-01 | RATIONALE: Penicillamine may stop the growth of glioblastomas by stopping blood flow to the tumor. A diet low in copper may interfere with the growth of brain tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining these therapies may be effective in treating glioblastoma. PURPOSE: Phase II trial to study the effectiveness of penicillamine, a low copper diet, and radiation therapy in treating patients who have newly diagnosed glioblastoma. |
| NCT00003751 ↗ | Penicillamine, Low Copper Diet, and Radiation Therapy in Treating Patients With Glioblastoma | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 | 1999-03-01 | RATIONALE: Penicillamine may stop the growth of glioblastomas by stopping blood flow to the tumor. A diet low in copper may interfere with the growth of brain tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining these therapies may be effective in treating glioblastoma. PURPOSE: Phase II trial to study the effectiveness of penicillamine, a low copper diet, and radiation therapy in treating patients who have newly diagnosed glioblastoma. |
| NCT00161148 ↗ | Probiotics in Patients With Primary Sclerosing Cholangitis | Unknown status | UMC Utrecht | Phase 3 | 2005-01-01 | PSC is a progressive liver disease without effective medical treatment. There is often co-existent ulcerative colitis. Probiotics (bacterial food supplements) have been shown to benefit patients with ulcerative colitis. In the current protocol potential beneficial effects of probiotics on liver biochemistry and liver related symptoms as pruritus are being assessed in 12 PSC patients in a randomized controlled cross over study (3 months probiotics, 1 one wash-out and 3 months placebo). |
| NCT00212355 ↗ | Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson's Disease in Japan. | Completed | Nobelpharma | Phase 3 | 2005-03-01 | The purpose of this long-term study is to determine whether Zinc Acetate is effective and safe in the treatment of Wilson's disease among Japanese. |
| NCT00246064 ↗ | The Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) Protocol | Completed | Centocor Ortho Biotech Services, L.L.C. | Phase 4 | 2001-12-01 | The purpose of the study was to evaluate the ability of a maintenance dosage regimen of infliximab to achieve and sustain at least 40% improvement from baseline in the total joint count in patients with active Rheumatoid Arthritis (RA) during methotrexate tapering. |
| NCT00369928 ↗ | Evaluation of 2 Oral Doses of PG-760564 in Rheumatoid Arthritis (RA) Patients Receiving Methotrexate | Completed | Procter and Gamble | Phase 2 | 2006-08-01 | This will be a 12-week, double-blind, randomized, placebo-controlled, parallel group, multicenter study to evaluate the safety, efficacy, and PK of oral administration of PG-760564 in adult patients with active RA receiving treatment with MTX. Two oral doses of PG-760564 will be evaluated: 25 mg BID and 100 mg BID. The study will consist of a screening visit followed by a washout period for all disease modifying antirheumatic drugs (DMARDs) and anti-cytokine therapies except MTX. After the washout period, patients determined to be eligible will be randomized to receive either 25 mg BID or 100 mg BID of oral PG-760564, or placebo for 12 weeks. There will be 6 treatment visits and a follow-up visit 4 weeks after the last treatment visit. The primary efficacy endpoint will be the proportion of patients meeting the ACR 20 response criteria after 12 weeks of treatment. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for penicillamine
Condition Name
Clinical Trial Locations for penicillamine
Trials by Country
Clinical Trial Progress for penicillamine
Clinical Trial Phase
Clinical Trial Sponsors for penicillamine
Sponsor Name
